This has led to the approval of the CXCR4 antagonist plerixafor (AMD3100) as a hematopoietic precursor mobilisation agent, which releases HSCs into the peripheral blood for collection and subsequent autologous transplantation in Non-Hodgkin lymphoma (NHL) or MM patients [93]. This evidence concerns the gene CXCR4 and Miyoshi myopathy.